<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01503021</url>
  </required_header>
  <id_info>
    <org_study_id>RMTI-SFP-6</org_study_id>
    <nct_id>NCT01503021</nct_id>
  </id_info>
  <brief_title>Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockwell Medical Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rockwell Medical Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the parent study is to assess the short-term safety and tolerability of
      soluble ferric pyrophosphate (SFP) in dialysate administered to a large number of
      representative adult chronic kidney disease patients on hemodialysis (CKD-HD).

      The purpose of the extension study is to assess the long-term safety and tolerability of SFP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parent Study: randomized, double-blinded, crossover, up to 6 weeks, 700 patients. Patients
      were randomized to receive SFP 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate
      concentrate or placebo (standard liquid bicarbonate concentrate) x 2 weeks, then a 1 week
      washout, then crossed over to the alternate treatment x 2 weeks.

      Extension Study: open-label, single active arm, uncontrolled study, up to 53 weeks, 300
      patients. Following completion of the RMTI-SFP-6 parent study, patients could enter the
      extension study, where they received SFP 2 µmoles (110 µg) iron/L of dialysate in liquid
      bicarbonate concentrate for up to 52 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-emergent Adverse Events</measure>
    <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
    <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-emergent Adverse Events of Intradialytic Hypotension</measure>
    <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
    <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. For each adverse event, investigators assessed whether the event met the protocol criteria for intradialytic hypotension. Intradialytic hypotension events were only to have been reported as adverse events if they exceeded the individual subject's baseline pattern of intradialytic hypotension.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Related Suspected Hypersensitivity Reactions</measure>
    <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
    <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. For each adverse event, investigators assessed whether the event met protocol criteria for suspected hypersensitivity reactions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Composite Cardiovascular Events</measure>
    <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
    <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Adverse event terms meeting criteria for composite cardiovascular events were pre-specified in the statistical analysis plan for the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hemodialysis Vascular Access Thrombotic Events</measure>
    <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
    <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Adverse event terms meeting criteria for hemodialysis vascular access thrombotic events were pre-specified in the statistical analysis plan for the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Other Thrombotic Events</measure>
    <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
    <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Adverse event terms meeting criteria for other thrombotic events were pre-specified in the statistical analysis plan for the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Systemic/Serious Infections</measure>
    <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
    <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Adverse events of systemic/serious infections were defined in the statistical analysis plan for the study to include infections for which the subject was administered at least 3 doses of an IV antibiotic, and infections for which the subject was hospitalized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
    <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. For each adverse event, investigators assessed whether the event met seriousness criteria.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum Iron Change From Pre-dialysis to Post-dialysis at Week 2</measure>
    <time_frame>Pre-dialysis and post-dialysis during study week 2 of the Parent (Crossover) Study</time_frame>
    <description>Serum iron was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 2. Because of the crossover nature of the study, the week 2 values reflect effects of SFP in the SFP/Placebo arm and effects of Placebo in the Placebo/SFP arm.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Iron Change From Pre-dialysis to Post-dialysis at Week 5</measure>
    <time_frame>Pre-dialysis and post-dialysis during study week 5 of the Parent (Crossover) Study</time_frame>
    <description>Serum iron was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 5. Because of the crossover nature of the study, the week 5 values reflect effects of Placebo in the SFP/Placebo arm and effects of SFP in the Placebo/SFP arm.</description>
  </other_outcome>
  <other_outcome>
    <measure>Unsaturated Iron-binding Capacity Change From Pre-dialysis to Post-dialysis at Week 2</measure>
    <time_frame>Pre-dialysis and post-dialysis during study week 2 of the Parent (Crossover) Study</time_frame>
    <description>Unsaturated iron-binding capacity was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 2. Because of the crossover nature of the study, the week 2 values reflect effects of SFP in the SFP/Placebo arm and effects of Placebo in the Placebo/SFP arm.</description>
  </other_outcome>
  <other_outcome>
    <measure>Unsaturated Iron-binding Capacity Change From Pre-dialysis to Post-dialysis at Week 5</measure>
    <time_frame>Pre-dialysis and post-dialysis during study week 5 of the Parent (Crossover) Study</time_frame>
    <description>Unsaturated iron-binding capacity was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 5. Because of the crossover nature of the study, the week 5 values reflect effects of Placebo in the SFP/Placebo arm and effects of SFP in the Placebo/SFP arm.</description>
  </other_outcome>
  <other_outcome>
    <measure>Transferrin Saturation Change From Pre-dialysis to Post-dialysis at Week 2</measure>
    <time_frame>Pre-dialysis and post-dialysis during study week 2 of the Parent (Crossover) Study</time_frame>
    <description>Transferrin saturation (based on TIBC derived from transferrin levels) was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 2. Because of the crossover nature of the study, the week 2 values reflect effects of SFP in the SFP/Placebo arm and effects of Placebo in the Placebo/SFP arm.</description>
  </other_outcome>
  <other_outcome>
    <measure>Transferrin Saturation Change From Pre-dialysis to Post-dialysis at Week 5</measure>
    <time_frame>Pre-dialysis and post-dialysis during study week 5 of the Parent (Crossover) Study</time_frame>
    <description>Transferrin saturation (based on TIBC derived from transferrin levels) was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 5. Because of the crossover nature of the study, the week 5 values reflect effects of Placebo in the SFP/Placebo arm and effects of SFP in the Placebo/SFP arm.</description>
  </other_outcome>
  <other_outcome>
    <measure>Ferritin</measure>
    <time_frame>Baseline, up to 53 weeks for Extension Study</time_frame>
    <description>The baseline and end of treatment predialysis ferritin levels were evaluated for the 52-week extension study to determine whether soluble ferric pyrophosphate increases iron stores.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Iron</measure>
    <time_frame>Baseline, up to 53 weeks for Extension Study</time_frame>
    <description>The baseline and end of treatment predialysis serum iron levels were evaluated for the 52-week extension study to determine the effect of soluble ferric pyrophosphate on serum iron.</description>
  </other_outcome>
  <other_outcome>
    <measure>Transferrin Saturation</measure>
    <time_frame>Baseline, up to 53 weeks for Extension Study</time_frame>
    <description>The baseline and end of treatment predialysis transferrin saturation were evaluated for the 52-week extension study to confirm clearance of iron derived from soluble ferric pyrophosphate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Patients Meeting Hy's Law Criteria</measure>
    <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
    <description>The peak alanine aminotransferase and the peak total bilirubin levels were evaluated per patient. Laboratory values for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Patients with alanine aminotransferase more than three times the upper limit of normal and also total bilirubin more than two times the upper limit of normal are counted.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">718</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>SFP/Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks, then 1 week washout, then standard liquid bicarbonate concentrate without SFP x 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/SFP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard liquid bicarbonate concentrate without SFP x 2 weeks, then 1 week washout, then soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SFP</intervention_name>
    <description>Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate</description>
    <arm_group_label>SFP/Placebo</arm_group_label>
    <arm_group_label>Placebo/SFP</arm_group_label>
    <other_name>Soluble ferric pyrophosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dialysis with standard liquid bicarbonate concentrate without iron</description>
    <arm_group_label>SFP/Placebo</arm_group_label>
    <arm_group_label>Placebo/SFP</arm_group_label>
    <other_name>Standard liquid bicarbonate concentrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Parent Study, Double Blinded, Crossover:

        Key Inclusion Criteria:

          1. Adult ≥ 18 years of age.

          2. Has chronic kidney disease (CKD) receiving maintenance hemodialysis (HD) (CKD-HD
             subjects) and regularly undergoing 2 or more dialysis sessions per week.

          3. Stable pre-dialysis Hgb ≥ 9.0 to ≤ 12.5 g/dL.

          4. Stable pre-dialysis TSAT ≥ 15% to ≤ 45%.

          5. Stable pre-dialysis ferritin ≥ 100 to ≤ 1200 µg/L (1200 ng/mL).

        Key Exclusion Criteria:

          1. Any previous exposure to SFP.

          2. Therapy with intravenous, intramuscular or oral iron at any time between the
             first/screening visit and the randomization visit, or anticipated requirement for iron
             supplementation during the study period.

          3. Non-tunneled vascular catheter for dialysis.

          4. Scheduled for kidney transplant within the next 8 weeks.

          5. Active infection requiring systemic antimicrobial or antifungal therapy within 2 weeks
             prior to screening, or during screening period prior to randomization.

          6. Hospitalization within 1 month prior to screening (except for vascular access
             surgery).

        Extension Study, Open Label, Single Active Arm:

        Key Inclusion Criteria:

          1. Participated in Parent Study RMTI-SFP-6 and completed the follow-up/early term visit.

          2. Hemoglobin ≤12.0 g/dL at screening.

          3. TSAT ≤45% at screening. (Excursion of TSAT by ≤10% outside this range permitted only
             if all other inclusion/exclusion criteria are met).

          4. Serum ferritin ≤1000 µg/L at screening. (Excursion of ferritin by ≤10% outside this
             range permitted only if all other inclusion/exclusion criteria are met).

        Key Exclusion Criteria:

          1. Had a serious adverse event attributable (i.e., probably, possibly, or definitely
             related) to study drug or had an adverse event attributable to study drug that
             necessitated premature withdrawal from the double-blind, placebo-controlled crossover
             phase of the parent study RMTI-SFP-6.

          2. Non-tunneled vascular catheter for dialysis.

          3. Scheduled for kidney transplant within 12 weeks after entry into extension phase.

          4. Active infection requiring systemic antimicrobial or antifungal therapy within 2 weeks
             prior to dosing.

          5. Pregnancy or intention to become pregnant during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ray Pratt, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rockwell Medical, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36688</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arvada</city>
        <state>Colorado</state>
        <zip>80002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westminster</city>
        <state>Colorado</state>
        <zip>80031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Indiana</state>
        <zip>47201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camp Springs</city>
        <state>Maryland</state>
        <zip>20748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gulfport</city>
        <state>Mississippi</state>
        <zip>39501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McComb</city>
        <state>Mississippi</state>
        <zip>39648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mission</city>
        <state>Texas</state>
        <zip>78572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Courtice</city>
        <state>Ontario</state>
        <zip>L1E 3C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>54P 0W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2011</study_first_submitted>
  <study_first_submitted_qc>December 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2012</study_first_posted>
  <results_first_submitted>April 3, 2015</results_first_submitted>
  <results_first_submitted_qc>April 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 21, 2015</results_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Soluble ferric pyrophosphate</keyword>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Chronic hemodialysis</keyword>
  <keyword>Ferric pyrophosphate citrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dialysis Solutions</mesh_term>
    <mesh_term>Iron</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SFP/Placebo</title>
          <description>Soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks, then 1 week washout, then standard liquid bicarbonate concentrate without SFP x 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo/SFP</title>
          <description>Standard liquid bicarbonate concentrate without SFP x 2 weeks, then 1 week washout, then soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="360"/>
                <participants group_id="P2" count="358"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dosed</title>
              <participants_list>
                <participants group_id="P1" count="351"/>
                <participants group_id="P2" count="352"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment</title>
              <participants_list>
                <participants group_id="P1" count="333"/>
                <participants group_id="P2" count="333">One patient completed the treatment period but discontinued prior to completing the follow-up visit.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="333"/>
                <participants group_id="P2" count="332"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved, received transplant, etc.</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>SFP/Placebo</title>
          <description>Soluble ferric pyrophosphate (SFP) 2 µM (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks, then 1 week washout, then standard liquid bicarbonate concentrate without SFP x 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo/SFP</title>
          <description>Standard liquid bicarbonate concentrate without SFP x 2 weeks, then 1 week washout, then soluble ferric pyrophosphate (SFP) 2 µM (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="351"/>
            <count group_id="B2" value="352"/>
            <count group_id="B3" value="703"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.9" spread="13.18"/>
                    <measurement group_id="B2" value="59.5" spread="13.30"/>
                    <measurement group_id="B3" value="59.7" spread="13.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="246"/>
                    <measurement group_id="B3" value="507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Treatment-emergent Adverse Events</title>
        <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention.</description>
        <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>Soluble Ferric Pyrophosphate</title>
            <description>Parent Study: Blinded soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Parent Study: Blinded standard liquid bicarbonate concentrate</description>
          </group>
          <group group_id="O3">
            <title>Open-label Soluble Ferric Pyrophosphate</title>
            <description>Extension Study: Open-label soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment-emergent Adverse Events</title>
          <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="693"/>
                <count group_id="O2" value="687"/>
                <count group_id="O3" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6"/>
                    <measurement group_id="O2" value="35.1"/>
                    <measurement group_id="O3" value="95.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Treatment-emergent Adverse Events of Intradialytic Hypotension</title>
        <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. For each adverse event, investigators assessed whether the event met the protocol criteria for intradialytic hypotension. Intradialytic hypotension events were only to have been reported as adverse events if they exceeded the individual subject's baseline pattern of intradialytic hypotension.</description>
        <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>Soluble Ferric Pyrophosphate</title>
            <description>Parent Study: Blinded soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Parent Study: Blinded standard liquid bicarbonate concentrate</description>
          </group>
          <group group_id="O3">
            <title>Open-label Soluble Ferric Pyrophosphate</title>
            <description>Extension Study: Open-label soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment-emergent Adverse Events of Intradialytic Hypotension</title>
          <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. For each adverse event, investigators assessed whether the event met the protocol criteria for intradialytic hypotension. Intradialytic hypotension events were only to have been reported as adverse events if they exceeded the individual subject's baseline pattern of intradialytic hypotension.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="693"/>
                <count group_id="O2" value="687"/>
                <count group_id="O3" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="4.9"/>
                    <measurement group_id="O3" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Related Suspected Hypersensitivity Reactions</title>
        <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. For each adverse event, investigators assessed whether the event met protocol criteria for suspected hypersensitivity reactions.</description>
        <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>Soluble Ferric Pyrophosphate</title>
            <description>Parent Study: Blinded soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Parent Study: Blinded standard liquid bicarbonate concentrate</description>
          </group>
          <group group_id="O3">
            <title>Open-label Soluble Ferric Pyrophosphate</title>
            <description>Extension Study: Open-label soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Related Suspected Hypersensitivity Reactions</title>
          <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. For each adverse event, investigators assessed whether the event met protocol criteria for suspected hypersensitivity reactions.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="693"/>
                <count group_id="O2" value="687"/>
                <count group_id="O3" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Composite Cardiovascular Events</title>
        <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Adverse event terms meeting criteria for composite cardiovascular events were pre-specified in the statistical analysis plan for the study.</description>
        <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>Soluble Ferric Pyrophosphate</title>
            <description>Parent Study: Blinded soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Parent Study: Blinded standard liquid bicarbonate concentrate</description>
          </group>
          <group group_id="O3">
            <title>Open-label Soluble Ferric Pyrophosphate</title>
            <description>Extension Study: Open-label soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite Cardiovascular Events</title>
          <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Adverse event terms meeting criteria for composite cardiovascular events were pre-specified in the statistical analysis plan for the study.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="693"/>
                <count group_id="O2" value="687"/>
                <count group_id="O3" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hemodialysis Vascular Access Thrombotic Events</title>
        <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Adverse event terms meeting criteria for hemodialysis vascular access thrombotic events were pre-specified in the statistical analysis plan for the study.</description>
        <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>Soluble Ferric Pyrophosphate</title>
            <description>Parent Study: Blinded soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Parent Study: Blinded standard liquid bicarbonate concentrate</description>
          </group>
          <group group_id="O3">
            <title>Open-label Soluble Ferric Pyrophosphate</title>
            <description>Extension Study: Open-label soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hemodialysis Vascular Access Thrombotic Events</title>
          <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Adverse event terms meeting criteria for hemodialysis vascular access thrombotic events were pre-specified in the statistical analysis plan for the study.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="693"/>
                <count group_id="O2" value="687"/>
                <count group_id="O3" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.6"/>
                    <measurement group_id="O3" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Other Thrombotic Events</title>
        <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Adverse event terms meeting criteria for other thrombotic events were pre-specified in the statistical analysis plan for the study.</description>
        <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>Soluble Ferric Pyrophosphate</title>
            <description>Parent Study: Blinded soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Parent Study: Blinded standard liquid bicarbonate concentrate</description>
          </group>
          <group group_id="O3">
            <title>Open-label Soluble Ferric Pyrophosphate</title>
            <description>Extension Study: Open-label soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Other Thrombotic Events</title>
          <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Adverse event terms meeting criteria for other thrombotic events were pre-specified in the statistical analysis plan for the study.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="693"/>
                <count group_id="O2" value="687"/>
                <count group_id="O3" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.1"/>
                    <measurement group_id="O3" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Systemic/Serious Infections</title>
        <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Adverse events of systemic/serious infections were defined in the statistical analysis plan for the study to include infections for which the subject was administered at least 3 doses of an IV antibiotic, and infections for which the subject was hospitalized.</description>
        <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>Soluble Ferric Pyrophosphate</title>
            <description>Parent Study: Blinded soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Parent Study: Blinded standard liquid bicarbonate concentrate</description>
          </group>
          <group group_id="O3">
            <title>Open-label Soluble Ferric Pyrophosphate</title>
            <description>Extension Study: Open-label soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Systemic/Serious Infections</title>
          <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Adverse events of systemic/serious infections were defined in the statistical analysis plan for the study to include infections for which the subject was administered at least 3 doses of an IV antibiotic, and infections for which the subject was hospitalized.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="693"/>
                <count group_id="O2" value="687"/>
                <count group_id="O3" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Serious Adverse Events</title>
        <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. For each adverse event, investigators assessed whether the event met seriousness criteria.</description>
        <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>Soluble Ferric Pyrophosphate</title>
            <description>Parent Study: Blinded soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Parent Study: Blinded standard liquid bicarbonate concentrate</description>
          </group>
          <group group_id="O3">
            <title>Open-label Soluble Ferric Pyrophosphate</title>
            <description>Extension Study: Open-label soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events</title>
          <description>Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. For each adverse event, investigators assessed whether the event met seriousness criteria.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="693"/>
                <count group_id="O2" value="687"/>
                <count group_id="O3" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="5.1"/>
                    <measurement group_id="O3" value="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Iron Change From Pre-dialysis to Post-dialysis at Week 2</title>
        <description>Serum iron was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 2. Because of the crossover nature of the study, the week 2 values reflect effects of SFP in the SFP/Placebo arm and effects of Placebo in the Placebo/SFP arm.</description>
        <time_frame>Pre-dialysis and post-dialysis during study week 2 of the Parent (Crossover) Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>SFP/Placebo</title>
            <description>Parent Study: Blinded soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate, then 1 week washout, then blinded standard liquid bicarbonate concentrate without SFP x 2 weeks
SFP: Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
Placebo: Dialysis with standard liquid bicarbonate concentrate without iron</description>
          </group>
          <group group_id="O2">
            <title>Placebo/SFP</title>
            <description>Parent Study: Blinded standard liquid bicarbonate concentrate without SFP x 2 weeks, then 1 week washout, then soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate x 2 weeks.
SFP: Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
Placebo: Dialysis with standard liquid bicarbonate concentrate without iron</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Iron Change From Pre-dialysis to Post-dialysis at Week 2</title>
          <description>Serum iron was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 2. Because of the crossover nature of the study, the week 2 values reflect effects of SFP in the SFP/Placebo arm and effects of Placebo in the Placebo/SFP arm.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.66" spread="5.435"/>
                    <measurement group_id="O2" value="13.65" spread="5.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.60" spread="10.151"/>
                    <measurement group_id="O2" value="14.97" spread="7.753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dialysis to post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.91" spread="9.243"/>
                    <measurement group_id="O2" value="1.36" spread="5.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Iron Change From Pre-dialysis to Post-dialysis at Week 5</title>
        <description>Serum iron was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 5. Because of the crossover nature of the study, the week 5 values reflect effects of Placebo in the SFP/Placebo arm and effects of SFP in the Placebo/SFP arm.</description>
        <time_frame>Pre-dialysis and post-dialysis during study week 5 of the Parent (Crossover) Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>SFP/Placebo</title>
            <description>Parent Study: Blinded soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate, then 1 week washout, then blinded standard liquid bicarbonate concentrate without SFP x 2 weeks
SFP: Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
Placebo: Dialysis with standard liquid bicarbonate concentrate without iron</description>
          </group>
          <group group_id="O2">
            <title>Placebo/SFP</title>
            <description>Parent Study: Blinded standard liquid bicarbonate concentrate without SFP x 2 weeks, then 1 week washout, then soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate x 2 weeks.
SFP: Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
Placebo: Dialysis with standard liquid bicarbonate concentrate without iron</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Iron Change From Pre-dialysis to Post-dialysis at Week 5</title>
          <description>Serum iron was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 5. Because of the crossover nature of the study, the week 5 values reflect effects of Placebo in the SFP/Placebo arm and effects of SFP in the Placebo/SFP arm.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.97" spread="4.731"/>
                    <measurement group_id="O2" value="13.02" spread="4.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.98" spread="7.884"/>
                    <measurement group_id="O2" value="37.79" spread="11.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dialysis to post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="6.834"/>
                    <measurement group_id="O2" value="24.82" spread="9.827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Unsaturated Iron-binding Capacity Change From Pre-dialysis to Post-dialysis at Week 2</title>
        <description>Unsaturated iron-binding capacity was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 2. Because of the crossover nature of the study, the week 2 values reflect effects of SFP in the SFP/Placebo arm and effects of Placebo in the Placebo/SFP arm.</description>
        <time_frame>Pre-dialysis and post-dialysis during study week 2 of the Parent (Crossover) Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>SFP/Placebo</title>
            <description>Parent Study: Blinded soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate, then 1 week washout, then blinded standard liquid bicarbonate concentrate without SFP x 2 weeks
SFP: Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
Placebo: Dialysis with standard liquid bicarbonate concentrate without iron</description>
          </group>
          <group group_id="O2">
            <title>Placebo/SFP</title>
            <description>Parent Study: Blinded standard liquid bicarbonate concentrate without SFP x 2 weeks, then 1 week washout, then soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate x 2 weeks.
SFP: Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
Placebo: Dialysis with standard liquid bicarbonate concentrate without iron</description>
          </group>
        </group_list>
        <measure>
          <title>Unsaturated Iron-binding Capacity Change From Pre-dialysis to Post-dialysis at Week 2</title>
          <description>Unsaturated iron-binding capacity was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 2. Because of the crossover nature of the study, the week 2 values reflect effects of SFP in the SFP/Placebo arm and effects of Placebo in the Placebo/SFP arm.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.95" spread="6.310"/>
                    <measurement group_id="O2" value="28.05" spread="7.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.44" spread="6.899"/>
                    <measurement group_id="O2" value="30.49" spread="8.909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dialysis to post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.47" spread="7.040"/>
                    <measurement group_id="O2" value="2.49" spread="4.910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Unsaturated Iron-binding Capacity Change From Pre-dialysis to Post-dialysis at Week 5</title>
        <description>Unsaturated iron-binding capacity was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 5. Because of the crossover nature of the study, the week 5 values reflect effects of Placebo in the SFP/Placebo arm and effects of SFP in the Placebo/SFP arm.</description>
        <time_frame>Pre-dialysis and post-dialysis during study week 5 of the Parent (Crossover) Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>SFP/Placebo</title>
            <description>Parent Study: Blinded soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate, then 1 week washout, then blinded standard liquid bicarbonate concentrate without SFP x 2 weeks
SFP: Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
Placebo: Dialysis with standard liquid bicarbonate concentrate without iron</description>
          </group>
          <group group_id="O2">
            <title>Placebo/SFP</title>
            <description>Parent Study: Blinded standard liquid bicarbonate concentrate without SFP x 2 weeks, then 1 week washout, then soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate x 2 weeks.
SFP: Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
Placebo: Dialysis with standard liquid bicarbonate concentrate without iron</description>
          </group>
        </group_list>
        <measure>
          <title>Unsaturated Iron-binding Capacity Change From Pre-dialysis to Post-dialysis at Week 5</title>
          <description>Unsaturated iron-binding capacity was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 5. Because of the crossover nature of the study, the week 5 values reflect effects of Placebo in the SFP/Placebo arm and effects of SFP in the Placebo/SFP arm.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.80" spread="6.745"/>
                    <measurement group_id="O2" value="29.05" spread="7.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.95" spread="8.488"/>
                    <measurement group_id="O2" value="12.41" spread="8.463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dialysis to post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="5.333"/>
                    <measurement group_id="O2" value="-16.68" spread="7.452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Transferrin Saturation Change From Pre-dialysis to Post-dialysis at Week 2</title>
        <description>Transferrin saturation (based on TIBC derived from transferrin levels) was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 2. Because of the crossover nature of the study, the week 2 values reflect effects of SFP in the SFP/Placebo arm and effects of Placebo in the Placebo/SFP arm.</description>
        <time_frame>Pre-dialysis and post-dialysis during study week 2 of the Parent (Crossover) Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>SFP/Placebo</title>
            <description>Parent Study: Blinded soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate, then 1 week washout, then blinded standard liquid bicarbonate concentrate without SFP x 2 weeks
SFP: Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
Placebo: Dialysis with standard liquid bicarbonate concentrate without iron</description>
          </group>
          <group group_id="O2">
            <title>Placebo/SFP</title>
            <description>Parent Study: Blinded standard liquid bicarbonate concentrate without SFP x 2 weeks, then 1 week washout, then soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate x 2 weeks.
SFP: Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
Placebo: Dialysis with standard liquid bicarbonate concentrate without iron</description>
          </group>
        </group_list>
        <measure>
          <title>Transferrin Saturation Change From Pre-dialysis to Post-dialysis at Week 2</title>
          <description>Transferrin saturation (based on TIBC derived from transferrin levels) was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 2. Because of the crossover nature of the study, the week 2 values reflect effects of SFP in the SFP/Placebo arm and effects of Placebo in the Placebo/SFP arm.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>percent transferrin saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.31" spread="11.357"/>
                    <measurement group_id="O2" value="30.46" spread="11.849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.85" spread="17.646"/>
                    <measurement group_id="O2" value="30.23" spread="14.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dialysis to post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.44" spread="17.442"/>
                    <measurement group_id="O2" value="-0.25" spread="10.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Transferrin Saturation Change From Pre-dialysis to Post-dialysis at Week 5</title>
        <description>Transferrin saturation (based on TIBC derived from transferrin levels) was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 5. Because of the crossover nature of the study, the week 5 values reflect effects of Placebo in the SFP/Placebo arm and effects of SFP in the Placebo/SFP arm.</description>
        <time_frame>Pre-dialysis and post-dialysis during study week 5 of the Parent (Crossover) Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>SFP/Placebo</title>
            <description>Parent Study: Blinded soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate, then 1 week washout, then blinded standard liquid bicarbonate concentrate without SFP x 2 weeks
SFP: Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
Placebo: Dialysis with standard liquid bicarbonate concentrate without iron</description>
          </group>
          <group group_id="O2">
            <title>Placebo/SFP</title>
            <description>Parent Study: Blinded standard liquid bicarbonate concentrate without SFP x 2 weeks, then 1 week washout, then soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate x 2 weeks.
SFP: Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
Placebo: Dialysis with standard liquid bicarbonate concentrate without iron</description>
          </group>
        </group_list>
        <measure>
          <title>Transferrin Saturation Change From Pre-dialysis to Post-dialysis at Week 5</title>
          <description>Transferrin saturation (based on TIBC derived from transferrin levels) was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 5. Because of the crossover nature of the study, the week 5 values reflect effects of Placebo in the SFP/Placebo arm and effects of SFP in the Placebo/SFP arm.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>percent transferrin saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.75" spread="10.302"/>
                    <measurement group_id="O2" value="28.88" spread="10.585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.73" spread="15.818"/>
                    <measurement group_id="O2" value="79.18" spread="20.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from pre-dialysis to post-dialysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="13.792"/>
                    <measurement group_id="O2" value="50.42" spread="18.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Ferritin</title>
        <description>The baseline and end of treatment predialysis ferritin levels were evaluated for the 52-week extension study to determine whether soluble ferric pyrophosphate increases iron stores.</description>
        <time_frame>Baseline, up to 53 weeks for Extension Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>Open-label Soluble Ferric Pyrophosphate</title>
            <description>Extension Study: Open-label soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
        </group_list>
        <measure>
          <title>Ferritin</title>
          <description>The baseline and end of treatment predialysis ferritin levels were evaluated for the 52-week extension study to determine whether soluble ferric pyrophosphate increases iron stores.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>micrograms per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="653.0" spread="288.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="520.3" spread="341.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-132.0" spread="311.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Iron</title>
        <description>The baseline and end of treatment predialysis serum iron levels were evaluated for the 52-week extension study to determine the effect of soluble ferric pyrophosphate on serum iron.</description>
        <time_frame>Baseline, up to 53 weeks for Extension Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>Open-label Soluble Ferric Pyrophosphate</title>
            <description>Extension Study: Open-label soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Iron</title>
          <description>The baseline and end of treatment predialysis serum iron levels were evaluated for the 52-week extension study to determine the effect of soluble ferric pyrophosphate on serum iron.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.650" spread="4.6488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.815" spread="5.3443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.772" spread="5.2686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Transferrin Saturation</title>
        <description>The baseline and end of treatment predialysis transferrin saturation were evaluated for the 52-week extension study to confirm clearance of iron derived from soluble ferric pyrophosphate.</description>
        <time_frame>Baseline, up to 53 weeks for Extension Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>Open-label Soluble Ferric Pyrophosphate</title>
            <description>Extension Study: Open-label soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
        </group_list>
        <measure>
          <title>Transferrin Saturation</title>
          <description>The baseline and end of treatment predialysis transferrin saturation were evaluated for the 52-week extension study to confirm clearance of iron derived from soluble ferric pyrophosphate.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>percent transferrin saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.050" spread="10.0504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.114" spread="11.5075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.835" spread="11.7221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Patients Meeting Hy's Law Criteria</title>
        <description>The peak alanine aminotransferase and the peak total bilirubin levels were evaluated per patient. Laboratory values for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Patients with alanine aminotransferase more than three times the upper limit of normal and also total bilirubin more than two times the upper limit of normal are counted.</description>
        <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
        <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>Soluble Ferric Pyrophosphate</title>
            <description>Parent Study: Blinded soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Parent Study: Blinded standard liquid bicarbonate concentrate</description>
          </group>
          <group group_id="O3">
            <title>Open-label Soluble Ferric Pyrophosphate</title>
            <description>Extension Study: Open-label soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Patients Meeting Hy's Law Criteria</title>
          <description>The peak alanine aminotransferase and the peak total bilirubin levels were evaluated per patient. Laboratory values for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Patients with alanine aminotransferase more than three times the upper limit of normal and also total bilirubin more than two times the upper limit of normal are counted.</description>
          <population>All participants who received at least one dose of study drug (SFP or placebo, as applicable).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="693"/>
                <count group_id="O2" value="687"/>
                <count group_id="O3" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study</time_frame>
      <desc>Adverse events for a given intervention are counted from the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Information regarding adverse events was elicited from participants using non-leading questions at each study visit, which generally occurred 3 times per week during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Soluble Ferric Pyrophosphate</title>
          <description>Parent Study: Blinded soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Parent Study: Blinded standard liquid bicarbonate concentrate</description>
        </group>
        <group group_id="E3">
          <title>Open-label Soluble Ferric Pyrophosphate</title>
          <description>Extension Study: Open-label soluble ferric pyrophosphate administered via the liquid bicarbonate concentrate to yield a final dialysate concentration of 2 micromolar (110 micrograms) iron/liter.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="144" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Device pacing issue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hepatic necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Chest wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Nasal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Areriovenous fistula aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Bone cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Uraemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Mediastinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Steal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Venous occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="253" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Haemodialysis-induced symptom</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="693"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="687"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, Clinical Research</name_or_title>
      <organization>Rockwell Medical, Inc</organization>
      <phone>248-960-9009</phone>
      <email>rd@rockwellmed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

